Xbiome is a developer of microbial pharmaceuticals designed to treat microecological intestinal disorders.
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to more quickly develop effective pharmaceuticals.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 22, 2021 | Series B | $100M | 1 | — | — | Detail |
Nov 27, 2020 | Funding Round | — | 2 | Gaorong Capital | — | Detail |
Nov 2, 2019 | Series B | ¥100M | 1 | — | — | Detail |
Jun 24, 2019 | Series A | $10M | 1 | Gaorong Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Gaorong Capital | — | Series B |
Yimei Capital | — | Funding Round |